Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
10,018 total articles
Olema Pharmaceuticals director Cyrus Harmon completed a sale of 10,000 shares on January 20, 2026, generating proceeds of $268,800 at an average share price of $26.88. This move occurs within the context of Olema's significant stock appreciation over the past year and elevated valuation. Several investment firms recently reiterated bullish ratings …
Warren Stone, President and Chief Operating Officer of Neogenomics Inc, sold over 22,000 shares valued at nearly $277,000 in a recent transaction. The company anticipates notable revenue increases for 2025 and has announced key leadership appointments while maintaining a solid financial position and legal victories.
Between January 19 and 21, 2026, Fine Capital Partners, together with affiliates Fine Capital Advisors and Debra Fine, sold Light & Wonder shares totaling approximately $3.67 million. Despite this sell-off, the firm maintains a substantial indirect holding exceeding 8 million shares. Light & Wonder recently reported mixed third-quarter 2025 earning…
Aparna Bawa, the Chief Operating Officer of Zoom Communications, sold nearly $987,553 worth of Class A common stock on January 16, 2026, through two separate transactions conducted under a prearranged trading plan. Despite this insider selling, Zoom maintains a strong balance sheet, high gross margins, and has recently reported earnings surpassing …
Caryn Parlavecchio, Chief Human Resources Officer of Scholar Rock Holding Corp, recently sold 6,600 shares of company stock to fulfill tax requirements tied to restricted stock units vesting. Concurrently, multiple analysts maintain positive outlooks on Scholar Rock’s lead drug candidate despite regulatory challenges and manufacturing partner scrut…
Mo Qatanani, Chief Scientific Officer at Scholar Rock Holding (NASDAQ:SRRK), executed a sale of 8,406 shares to satisfy tax obligations related to RSU vesting, while the company continues to advance regulatory submissions and attract analyst interest for its rare-disease therapies. Despite regulatory hurdles with its manufacturing partner, Scholar …
On January 16, 2026, Marantz Jing L., Chief Medical Officer at Scholar Rock Holding Corp (NASDAQ: SRRK), sold 5,798 shares of company stock to satisfy tax obligations tied to recently vested restricted stock units. This transaction occurs amid a series of analyst ratings and regulatory updates concerning Scholar Rock's lead candidate, apitegromab, …
Fairfax Financial Holdings and associated parties have expanded their ownership in Under Armour through a series of share acquisitions totaling nearly $50 million. These transactions took place across three separate days in January 2026, increasing their indirect holding to over 18 million shares. Meanwhile, Under Armour delivered an earnings beat …
Junlin Ho, General Counsel of Scholar Rock Holding Corp, completed a stock sale of over 8,000 shares to fulfill tax liabilities related to recent RSU vesting. This transaction occurs alongside significant corporate events including analyst endorsements and regulatory challenges as Scholar Rock advances its treatment candidate apitegromab.
Artur Bergman, Chief Technology Officer of Fastly, Inc., sold 20,000 shares of the company's Class A Common Stock in a transaction aligned with a pre-established trading plan. The sale, valuing approximately $163,600, comes as Fastly prepares to report upcoming earnings and executes strategic financial initiatives, including a convertible note offe…
Charles Lacey III, CEO of Fastly, Inc., has recently sold 13,682 shares of the company’s Class A Common Stock, netting roughly $123,000 in total. These transactions, disclosed in SEC filings, occurred as Fastly continues to navigate a challenging stock environment and advance strategic financial initiatives including a convertible note offering and…
Randall Moreadith, Chief Scientific Officer of Serina Therapeutics, completed the sale of a portion of his shares and exercised stock options on January 20 and 21, 2026. This insider activity coincides with the company receiving a notice from the NYSE citing deficiencies related to stockholders' equity and recent financial performance. Additionally…
Martin Small, CFO and Senior Managing Director of BlackRock, undertook sizable equity moves on January 16, 2026, selling over 27,000 shares for approximately $31.7 million. On the same day, he exercised options for an equal number of shares and acquired additional restricted stock units. BlackRock recently released fourth-quarter 2025 results surpa…
Mitsui Sumitomo Insurance Co., LTD increased its ownership in W.R. Berkley Corp through multiple stock purchases totaling $42.6 million. These acquisitions were made at prices close to the current market value, reflecting confidence in a company that has maintained dividends for over five decades. Meanwhile, W.R. Berkley faces mixed analyst sentime…
Megan Chung, serving as General Counsel and Secretary of Ouster, Inc., sold 5,837 shares of company stock in a transaction valued at nearly $159,000 on January 16, 2026. The share price for this sale was $27.24 per share. This move coincides with ongoing volatility in Ouster’s stock, which has appreciated substantially over the past year but recent…
Annie Armstrong, LendingClub's Chief Risk Officer, executed major stock transactions totaling over $695,000 in value on January 16, 2026, including sales and acquisitions tied to performance awards. These moves align with LendingClub's recent announcements of a $100 million share repurchase program and strategic market entry steps, attracting optim…
Jill Bourland, a director at Isabella Bank Corp, has augmented her investment in the bank's stock by acquiring additional shares in two transactions totaling over $12,000. The bank's shares have shown strong performance over the past year, and the company recently strengthened its financial leadership with a new CFO appointment.
Michael Gerard, General Counsel at Cabaletta Bio, Inc., recently invested approximately $15,000 in company stock, signaling confidence amid the clinical-stage biotech's advancement in CAR T cell therapy development. The investment coincides with regulatory clearance for automated manufacturing and encouraging clinical trial results, contributing to…
